Pharma & Biotech — 2026年9月7日 週次レポート
Pharma & Biotechのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •The week's defining story is the CAR-T safety crisis: deaths in Novartis trials and the pause of Bristol Myers programs have introduced a material safety overhang over the autoimmune cell therapy space, potentially slowing the M&A wave and in vivo CAR-T investment that characterized the prior period. The industry must now resolve the acceptable-risk question in autoimmune CAR-T before the next wave of deals and trials can proceed with confidence.
- •Cardiovascular drug development is entering a credibility crisis: three major failures across different companies and mechanisms in rapid succession — AstraZeneca-Ionis gene silencing, Novo Nordisk's inflammation drug, and now Novartis's pivotal failure — suggest the indication is harder than pipeline valuations have assumed, with implications for R&D prioritization and investor confidence across the sector.
- •European pharma policy is opening a new regulatory front: the Advocate General's recommendation to annul the Urban Wastewater Treatment Directive's pharmaceutical cost provisions, combined with EFPIA's ongoing Biotech Act advocacy and the EU Multiannual Financial Framework positioning, signals that the European industry is systematically challenging regulatory cost burdens across multiple policy domains simultaneously.
- •The FDA's sustained rare disease and specialty approval cadence — Ionis Alexander disease, Protagonist/Takeda rare blood disorder, Roivant autoimmune — confirms that the agency's operational productivity is holding despite leadership uncertainty, while its tightening of foreign clinical trial data standards signals that geopolitical risk management is becoming embedded in routine FDA operations.
- •Merck's explicit M&A signaling and Lilly's 13th acquisition of 2026 indicate that large-cap deal-making is accelerating into Q4 2026, driven by patent cliff pressures and platform expansion imperatives — creating a competitive environment where mid-size biotechs with differentiated assets will face increasing acquisition pressure and valuation uplift.
今回の要点（12件）
- 1.Deaths in Novartis CAR-T trials forced a halt, with Bristol Myers Squibb programs also paused, per Endpoints News and STAT News on 2026-09-01 [8] — directly challenging the autoimmune CAR-T strategy multiple companies have been building.
- 2.Novartis's experimental cardiovascular drug failed a pivotal study on 2026-09-04 per STAT News [3], adding to a cluster of cardiovascular failures (AstraZeneca-Ionis, Novo Nordisk) that collectively raise questions about the cardiovascular development environment.
- 3.The FDA approved Ionis's Alexander disease drug on 2026-09-03 — the company's first solo neurology approval — per STAT News and Endpoints News [3] [8], signaling Ionis's strategic shift toward independent commercialization.
- 4.The FDA approved Protagonist and Takeda's drug as the first treatment for a rare blood disorder on 2026-08-30 per STAT News [3], and Roivant's therapy for a rare autoimmune disease on 2026-08-27 [3], sustaining the August approval cadence.
- 5.The Advocate General recommended annulment of key Urban Wastewater Treatment Directive provisions requiring pharma to finance at least 80% of quaternary treatment costs, per EFPIA on 2026-09-03 [1a].
- 6.Trump announced nine new drug pricing deals with mid-size biotechs on 2026-08-31 per STAT News [3], with subsequent reporting suggesting these deals may undermine broader drug cost containment efforts [3].
- 7.Merck's M&A chief publicly signaled expectations for 'a lot more deal flow' as the KEYTRUDA patent cliff nears, per Endpoints News on 2026-09-04 [8], telegraphing an accelerated acquisition posture.
- 8.Eli Lilly completed its 13th acquisition of 2026 by buying Merida Biosciences, per Endpoints News on 2026-08-31 [8], sustaining an unprecedented deal pace that is reshaping the biotech venture ecosystem.
- 9.The EMA launched a voluntary NAMs data submission pilot on 2026-09-01 to advance alternatives to animal testing [5], and the PRAC initiated a safety review of injectable iron-containing medicines on 2026-09-04 [5].
- 10.PMDA published its 2025 Regulatory Science Activity Report in English and new oral drug food effect guidance on 2026-09-03 [6], continuing its international harmonization cadence.
- 11.FDA leaders doubled down on oversight of foreign clinical trial data coinciding with China's rise as a trial hub, per Endpoints News on 2026-09-03 [8], extending the prior period's legislative pressure into operational FDA policy.
- 12.Merck KGaA agreed to acquire Bio-Techne for $11.3 billion, adding multiomics products and analytical technologies, per Nature Biotechnology on 2026-09-06 [14].
市場動向
FDA Approval Cadence Sustains Across Rare Disease and Oncology Into September
The week's approval activity continued the dense first-in-class pattern established in August. The FDA approved Ionis's drug for Alexander disease — described by STAT News as the company's first solo neurology approval — on 2026-09-03 [3]. The FDA also approved Protagonist and Takeda's drug as the first treatment for a rare blood disorder on 2026-08-30 [3]. Roivant's therapy for a rare autoimmune disease received FDA approval on 2026-08-27 [3]. Together these approvals signal that the FDA's high…
Cardiovascular Drug Failures Accumulate, Raising Modality-Level Questions
Novartis's experimental cardiovascular drug failed a pivotal study, reported by STAT News on 2026-09-04 [3]. This follows the AstraZeneca-Ionis gene silencer failure in heart disease from the prior week and Novo Nordisk's cardiovascular drug failure. The accumulation of cardiovascular trial failures across different companies and mechanisms — gene silencing, IL-6 inhibition, and other modalities — suggests the cardiovascular development environment is becoming more challenging, with implications…
CAR-T Safety Crisis Triggers Broad Trial Halts and Autoimmune Risk Reassessment
Deaths in Novartis CAR-T trials prompted a halt, with Bristol Myers Squibb programs also paused, reported by Endpoints News on 2026-09-01 [8]. STAT News reported on 2026-09-01 that Novartis and Bristol were pausing cell therapy trials [3]. The crisis is forcing a reckoning over acceptable risk in autoimmune disease, per Endpoints News [8]. This directly impacts the in vivo CAR-T autoimmune strategy that J&J and others have been building, and may slow the autoimmune M&A wave documented in the pri…
Trump Drug Pricing Deals Expand to Mid-Size Biotechs, Raising Policy Uncertainty
The Trump administration announced nine new drug pricing deals with mid-size biotechs on 2026-08-31, per STAT News [3] and Endpoints News [8]. STAT News subsequently reported on 2026-09-02 that these deals may undermine efforts to rein in drug costs [3], and raised five burning questions about the deals' implications for patients, companies, and policymakers [3]. The expansion of pricing deals from large pharma to mid-size biotechs broadens the policy's market impact and introduces new uncertain…
mRNA Platform Momentum Continues With Multiple Sclerosis and Radiopharmaceutical Advances
Novartis's BTK inhibitor Rhapsido showed Phase 3 multiple sclerosis wins, per Endpoints News on 2026-09-01 [8] and STAT News [3]. Separately, STAT News reported on 2026-08-31 that a cadre of radiopharmaceuticals experts is pushing the bounds in cancer therapy [3], and ARPA-H awarded $125M for manufacturing custom RNA therapies on demand per Endpoints News on 2026-09-02 [8]. These developments indicate that advanced therapy modalities — BTK inhibition, radiopharmaceuticals, and RNA therapeutics —…
競合動向
Novartis Faces Simultaneous CAR-T Safety Crisis and Cardiovascular Pivotal Failure
Novartis experienced two major setbacks in the same week: deaths in its CAR-T trials forced a halt (with Bristol Myers programs also paused) per Endpoints News on 2026-09-01 [8], and its experimental cardiovascular drug failed a pivotal study per STAT News on 2026-09-04 [3]. These simultaneous failures across two high-priority therapeutic areas — autoimmune cell therapy and cardiovascular — represent a significant competitive setback, even as Novartis's BTK inhibitor Rhapsido showed Phase 3 MS w…
Ionis Achieves First Solo Neurology Approval, Expanding Beyond Antisense Partnerships
Ionis won FDA clearance for its Alexander disease drug — described by Endpoints News as the company's first solo neurology approval — on 2026-09-03 [8], corroborated by STAT News [3]. This milestone is strategically significant: Ionis has historically commercialized through partnerships (e.g., with AstraZeneca and Biogen), and a solo approval signals a shift toward independent commercial execution. The approval also comes as Arrowhead claims a safety edge over Ionis in the triglyceride market pe…
J&J Maintains Multi-Front Momentum With Investor Conference Participation and Pipeline Continuity
J&J announced participation in the Deutsche Bank 2026 Healthcare Summit on 2026-09-02 and scheduled an investor conference call on third-quarter results on 2026-08-31 [2] (company announcements — may reflect promotional framing). The RYBREVANT FASPRO Priority Review for head and neck cancer and IMAAVY's first-ever wAIHA approval from the prior period remain the most recent substantive pipeline milestones. J&J's competitive posture this week is consolidation and investor communication rather than…
Merck Signals Accelerated M&A Posture as KEYTRUDA Patent Cliff Approaches
Merck's M&A chief stated expectations for 'a lot more deal flow' as the KEYTRUDA patent cliff nears, per Endpoints News on 2026-09-04 [8]. Merck also participated in the Wells Fargo 21st Annual Healthcare Conference on 2026-09-02 [4] (company announcement — may reflect promotional framing). The explicit public signaling of accelerated deal-making by Merck's M&A leadership is a competitive signal to potential targets and partners that Merck is actively seeking to replace KEYTRUDA revenue — a dyna…
Eli Lilly Executes 13th Acquisition of 2026, Sustaining Unprecedented Deal Pace
Eli Lilly completed its 13th acquisition of 2026 by buying TED startup Merida Biosciences, per Endpoints News on 2026-08-31 [8]. Lilly's dealmaking was described as spreading wealth among a broad set of biotech venture investors [8]. This acquisition pace — 13 deals in under nine months — is structurally reshaping the biotech venture ecosystem by providing exit liquidity and validating early-stage programs across multiple therapeutic areas. Lilly's sustained acquisition cadence is a competitive …
制度・規制動向
EFPIA Challenges Urban Wastewater Directive Cost Allocation on Scientific Grounds
On 2026-09-03, EFPIA issued a statement welcoming the Advocate General's opinion recommending annulment of key provisions of the Urban Wastewater Treatment Directive that require pharmaceutical and cosmetics producers to finance at least 80% of quaternary wastewater treatment costs [1a]. The Advocate General identified serious deficiencies in the methodology used to calculate toxic load and insufficient assessment of other micropollutant sources. EFPIA called on the European Commission to pause …
EMA Launches Voluntary NAMs Pilot and Initiates Injectable Iron Safety Review
The EMA launched a voluntary data submission pilot on 2026-09-01 allowing developers to submit New Approach Methodologies (NAMs) data — innovative alternatives to animal testing — and receive tailored feedback [5]. Separately, the EMA's PRAC started a safety review of injectable iron-containing medicines on 2026-09-04 [5]. The NAMs pilot represents a structural shift in EMA's approach to preclinical evidence, potentially reducing animal testing requirements over time, while the iron safety revie…
EMA Addresses Visudyne Medicine Shortage With New EU Supply Chain
The EMA announced on 2026-09-04 that a new EU supply chain has been established to end the critical shortage of Visudyne (an eye medicine), with the shortage expected to be resolved in 2027 [5]. This action reflects the EMA's active role in medicines security — a theme that aligns with EFPIA's broader advocacy on supply chain resilience and the October 2026 HCI event on medicines shortages [1].
PMDA Publishes Regulatory Science Annual Report and New Oral Drug Food Effect Guidance
Japan's PMDA published its 2025 Regulatory Science Activity Report in English on 2026-09-03 and released an English translation of its guidance on evaluating food effects on oral drug formulations (Early Consideration) on the same date [6]. The PMDA also published Japanese Pharmacopoeia public comment materials on 2026-09-01 [6]. These publications reflect PMDA's continued international harmonization efforts and transparency in regulatory science, building on its sustained modernization cadence …
FDA Tightens Oversight of Foreign Clinical Trial Data Amid China Safety Concerns
FDA leaders doubled down on clinical trial oversight measures to ensure research data generated outside the US are adequate, per Endpoints News on 2026-09-03 [8], coinciding with China's rise as a clinical trial hub and following deaths in Chinese trials. The FDA also launched a pilot offering generative AI medical devices a path to patients before authorization, per STAT News on 2026-09-03 [3]. These parallel moves — tightening foreign data standards while opening AI device pathways — reflect t…
ソース活動
先週からの変化
Novartis CAR-T Trial Deaths Force Halt; Bristol Myers Programs Also Paused
Deaths in Novartis CAR-T trials prompted a halt, with Bristol Myers Squibb programs also paused, per Endpoints News and STAT News on 2026-09-01 [8] [3]. The crisis is forcing a reckoning over acceptable risk in autoimmune disease and directly impacts the in vivo CAR-T strategies multiple companies have been building.
EFPIA Challenges Urban Wastewater Directive — Advocate General Recommends Annulment
On 2026-09-03, EFPIA welcomed the Advocate General's opinion recommending annulment of provisions requiring pharma and cosmetics producers to finance at least 80% of quaternary wastewater treatment costs, citing deficiencies in toxic load methodology and insufficient micropollutant source assessment [1a]. EFPIA called for a pause in implementation and a comprehensive impact assessment.
Novartis Cardiovascular Pivotal Study Failure
Novartis's experimental cardiovascular drug failed a pivotal study, per STAT News on 2026-09-04 [3]. This adds to the accumulating cardiovascular trial failures across the industry (AstraZeneca-Ionis, Novo Nordisk) and raises modality-level questions about cardiovascular drug development.
Trump Drug Pricing Deals Expand to Nine Mid-Size Biotechs
The Trump administration announced nine new drug pricing deals with mid-size biotechs on 2026-08-31, per STAT News [3] and Endpoints News [8]. This updates the prior period's large-pharma pricing deal activity, expanding the policy's reach to smaller companies and raising new questions about its impact on drug cost containment efforts.
EMA Launches NAMs Voluntary Pilot and Initiates Injectable Iron Safety Review
The EMA launched a voluntary New Approach Methodologies (NAMs) data submission pilot on 2026-09-01 to advance innovative alternatives to animal testing [5], and the PRAC started a safety review of injectable iron-containing medicines on 2026-09-04 [5]. These represent new EMA regulatory science and pharmacovigilance initiatives this period.
ウォッチリスト — 今後の締切
EMA: Visudyne critical shortage expected to be resolved — new EU supply chain target date
ソース: EMA News示唆・見るべき論点（7件）
- 1.The CAR-T safety crisis in autoimmune disease — deaths in Novartis trials and Bristol Myers program pauses [8] — creates a direct headwind for J&J's $2.58B Sail Biomedicines in vivo CAR-T collaboration announced in the prior period. The industry's risk-benefit calculus for cell therapy in non-oncology indications is being reset in real time, and companies with autoimmune CAR-T programs should expect heightened regulatory scrutiny and investor skepticism until the safety signal is fully character…
- 2.The accumulation of cardiovascular pivotal failures — AstraZeneca-Ionis gene silencing, Novo Nordisk's inflammation drug, and Novartis's pivotal failure [3] — suggests that cardiovascular drug development is experiencing a systematic difficulty that transcends individual program design. Companies with cardiovascular pipeline assets should reassess their trial designs, patient selection criteria, and endpoint choices against this emerging pattern before committing to late-stage investment.
- 3.Merck's public signaling of accelerated M&A as the KEYTRUDA patent cliff approaches [8] will structurally inflate valuations for oncology and immunology assets over the next 12–18 months. Biotech companies in these spaces should model Merck as a motivated buyer when setting financing and partnership strategies, as the company's stated urgency creates negotiating leverage for asset holders.
- 4.The Advocate General's recommendation to annul the Urban Wastewater Treatment Directive's pharmaceutical cost provisions [1a] represents a significant legal and policy win for the European pharma industry, but the outcome remains uncertain pending the Court of Justice ruling. Companies should monitor the timeline and prepare for both outcomes, as the Directive in its current form could materially impact European supply chain economics.
- 5.The EMA's voluntary NAMs pilot [5] is a structural precursor to formal regulatory credit for animal-testing alternatives — a development that will advantage companies that have invested in in vitro and computational preclinical platforms. Early participation in the pilot offers both scientific feedback and a first-mover positioning advantage as the EMA builds its NAMs evidence base.
- 6.Eli Lilly's 13th acquisition of 2026 [8] and Merck's explicit M&A signaling together indicate that the large-cap acquisition environment is intensifying heading into Q4 2026. Venture-backed biotechs in oncology, immunology, and metabolic disease should expect compressed timelines between Series B/C financing and acquisition conversations, as strategic buyers are actively competing for assets.
- 7.The FDA's operational tightening of foreign clinical trial data standards [8] — building on the prior period's legislative pressure — is transitioning from a policy signal to an operational reality. Companies relying on China-originated clinical data for US submissions should begin assessing whether their data packages will meet the evolving FDA scrutiny standard, particularly for programs where US-based confirmatory trials are not already planned.
信頼度サマリー
今週引用したソース 14 件あなたが選んだ 14 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
EFPIA statement on the Advocate General's opinion recommending annulment of Urban Wastewater Treatment Directive pharmaceutical cost provisions, and EFPIA's position on the EU Multiannual Financial Framework 2028-2034 published 2026-09-01.
J&J press releases covering Deutsche Bank Healthcare Summit participation, investor conference call scheduling, and continued visibility of IMAAVY approval and RYBREVANT FASPRO Priority Review from prior period.
STAT News reporting covering Novartis CAR-T trial deaths and program halts, Novartis cardiovascular pivotal failure, Ionis Alexander disease FDA approval, Protagonist/Takeda rare blood disorder approval, Roivant autoimmune approval, Trump drug pricing deals and their implications, FDA generative AI medical device pilot, and Ultragenyx Angelman syndrome trial failure.
Merck announcement of participation in the Wells Fargo 21st Annual Healthcare Conference on 2026-09-02.
EMA news covering voluntary NAMs data submission pilot launched 2026-09-01, PRAC safety review of injectable iron-containing medicines initiated 2026-09-04, new EU supply chain to end Visudyne shortage announced 2026-09-04, and EMA Executive Director speech at Duke-NUS Medical School 2026-09-04.
PMDA publications covering 2025 Regulatory Science Activity Report in English, oral drug food effect guidance English translation, Japanese Pharmacopoeia public comment materials, and Class I recall of fresh frozen plasma product, all published 2026-09-01 to 2026-09-04.
PIC/S background content on GMP harmonization — no new changes detected this week.
Endpoints News reporting covering Novartis CAR-T trial deaths and program halts, Ionis Alexander disease approval, Merck M&A chief signaling accelerated deal flow, Eli Lilly's 13th acquisition of 2026, Trump drug pricing deals with mid-size biotechs, FDA tightening of foreign clinical trial data oversight, Arrowhead vs. Ionis triglyceride competition, and ARPA-H $125M RNA therapy manufacturing award.
Nature Biotechnology reporting on Merck KGaA's $11.3 billion acquisition of Bio-Techne adding multiomics products and analytical technologies, and Pakistan biosafety rule amendments updating the GMO regulatory framework. Also new research articles on AI-enhanced virtual screening, prime editing advances, and engineered genomic attachment sites published 2026-09-01 to 2026-09-02.
Pfizer press releases — no new changes detected this week; background content from prior period remains current.
IFPMA statement at the 76th WHO Regional Committee for Africa on the ongoing Ebola Bundibugyo virus outbreak, marking 100 days since declaration and calling for PABS system reforms to encourage company engagement in pandemic preparedness.
FDA Drug News updates including new guidance on pharmacokinetics in patients with impaired hepatic function published 2026-09-02, and temporary policies for compounding starter parenteral nutrition drug products for neonates noted for 2026-09-08.
DIA Global coverage of FDA tightened expectations for biosimilar promotion and upcoming DIA-MHRA Global Summit on innovation pathways.
Nature Biotechnology news article reporting Merck KGaA's $11.3 billion acquisition of Bio-Techne and Pakistan's biosafety rule amendments updating the GMO regulatory framework.
Pharma & Biotechを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める